Establishment and Development:
The Hematology Department of Qilu Hospital of Shandong University was founded in 1959 by Professor Maohong Zhang. The Hematology Department of Qilu Hospital of Shandong University is a national clinical key specialty, one of the first doctoral programs and post-doctoral stations in China, the innovation studio of leading scientific and technological talents in Shandong Province, and the Clinical Medical Research Center of Hematology System Diseases in Shandong Province. It is a branch of the Institute of Hematology, Chinese Academy of Medical Sciences and the National Clinical Medical Research Center for Blood System Diseases, Peking University People's Hospital. The Hematology Laboratory under the Hematology Department of Shandong University Qilu Hospital is the third-level key laboratory of the State Administration of Traditional Chinese Medicine, the key discipline and key laboratory of Shandong Province during the "Eleventh Five-Year Plan" strengthening construction, and the provincial key Laboratory of Blood Immunology of Shandong Province. The establishment of cell morphology room, central laboratory, cell culture room, molecular biology laboratory, flow cytometry room and stem cell room to provide assistance for the diagnosis, assessment and differential diagnosis of hematological diseases in the whole hospital. At present, it can perform fusion gene quantitative analysis, chromosome analysis, FISH detection, immune typing, MAIPA, platelet function detection and many other leading laboratory tests in China.
Team Members:
Our team is composed of leading experts in their fields, young and passionate researchers, and support staff dedicated to excellence. Together, they work tirelessly to explore various aspects of hematology.Professor Jun Peng, Chief Physician, Professor, Ph.D./M.D. Advisor, Vice President of Qilu Hospital of Shandong University, Director of the Department of Hematology. He has published 14 papers in Blood as the corresponding/ co-corresponding author. As a principal investigator, he has undertaken nine national and ministerial levels research projects, such as the National Natural Science Foundation of China and the sub-project of the National Program on Key Basic Research Project of China (973 Program) of the Ministry of Science and Technology. Professor Peng is a member of the thrombosis and hemostasis group of the Chinese Society of Hematology, and the Professional Committee of Experimental Hematology，Chinese Society of Pathophysiology. He serves as the editorial board member of Thrombosis Journal, Thrombosis Research, Journal of Clinical Hematology and Chinese Journal of Hematology.
Shuqian Xu，Ph.D./M.D. Advisor, Taishan Scholar Young Expert，Researcher，Chief Physician，Master Tutor，Deputy Director of Red Cell Disease Department of Hematology. In recent years, she has published papers in Nature Genetics 、Blood 、Genes and Diseases and other journals.
Prof. Daoxin Ma majors in the field of hematology, specializing in molecular diagnostics, disease stratification, and personalized treatment of hematologic diseases. Holding a Doctor of Medicine degree, he advanced his expertise with postdoctoral research at the prestigious Karolinska Institute in Sweden. Now, he excels as a Chief Technician and doctoral supervisor, deeply involved in the clinical diagnosis and foundational research of blood diseases.
Miao Xu, she was named a Young Taishan Scholar of Shandong Province, a Qilu Young Scholar of Shandong University, appointed as a research fellow and doctoral supervisor at Shandong University in the same year, and began her standardized training as a resident doctor, continuing her basic and clinical research on platelet-related diseases.
Research Areas:
Jun Peng specializes in pathogenesis and of primary immune thrombocytopenia（ITP），and myelodysplastic syndromes（MDS），and dififferentiation of hematopoietic stem cells.
Shuqian Xu specializes in myelodysplastic syndromes（MDS）and gene therapy for hereditary diseases . She is committed to the applied research and exploration of thalassemia gene therapy, and uses CRISPR therapy technology to efficiently edit pathogenic targets, providing new ideas for the treatment of thalassemia.
Daoxin Ma focuses on the role of the bone marrow immune microenvironment in Acute Myeloid Leukemia (AML), specifically investigating immune imbalance and its impact on disease progression, drug resistance, and relapse, along with novel signaling pathways. Additionally, his studies include the role of gut microbiota and its metabolic products in AML, exploring how these factors affect disease development.
Miao Xu primary focus lies in unraveling the intricate mechanisms underpinning platelet-related diseases, including immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC), and thrombosis.
Research Achievements:
The Department of Hematology has 6 sub-specialties, including hemostasis and thrombosis, leukemia disease, hematopoietic stem cell transplantation, lymphocyte disease, plasma cell disease and red blood cell disease, which have strong academic influence in China. Among them, the research on primary immune thrombocytopenia has reached the international leading level, and the research on leukemia has reached the international and domestic leading level.
In the diagnosis and research of primary immune thrombocytopenia, the Department of Hematology established the theory of ITP immune intolerance, proposed the concept of "first-line combined therapy" for the first time, and took the lead in the RCT study of recombinant human TPO for the treatment of pregnancy complicated with ITP, solving the worldwide problem of no medicine for pregnancy complicated with ITP. ITP patient diagnosis and treatment data management system was established. At the same time, a series of determination tests on the pathogenesis of ITP have been established and promoted in 26 medical institutions in China, and more than 6,000 patients have applied ITP. The Department of Hematology led the development of the Chinese expert consensus on the diagnosis and treatment of adult primary immune thrombocytopenia in 2009, 2011, 2012, 2016, 2023, and the treatment guidelines for primary immune thrombocytopenia in 2018 and 2020.
In the diagnosis and research of leukemia, the Department of Hematology has conducted systematic and in-depth research from the three levels of basic medicine, translational medicine and clinical medicine to promote early warning, early diagnosis, early treatment and improve prognosis of leukemia. We have established a big data platform related to acute myeloid leukemia, a follow-up system of leukemia sample bank, a BCR-ABL(P210) detection and evaluation system for chronic myeloid leukemia (CML), and a flow cytometry MRD detection platform for leukemia, etc., improving the basic and clinical research system for leukemia, and fully revealing new mechanisms of leukemia pathogenesis and drug resistance. It has promoted the development of intelligent diagnosis and treatment technology for leukemia. The Department of Hematology led the development of expert consensus on the prevention and treatment of novel coronavirus infection in patients with inert B-cell non-Hodgkin lymphoma, and the Chinese expert Consensus on the detection and clinical interpretation of minimal residual disease in chronic lymphocytic leukemia (2023 edition).
Main Publications:
1. Liu Y#, Zuo X#, Chen P#, Hu X, Sheng Z, Liu A, Liu Q, Leng S, Zhang X, Li X, Wang L, Feng Q, Li C, Hou M, Chu C, Ma S*, Wang S*, Peng J*. Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia. Signal Transduct Target Ther. 2022 Oct 7;7(1):347. doi: 10.1038/s41392-022-01167-9.
2. Hou Y#*, Xie J#, Wang S#, Li D, Wang L, Wang H, Ni X, Leng S, Li G, Hou M, Peng J*. Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia. Cell Mol Immunol. 2022 Jul;19(7):764-776. doi: 10.1038/s41423-022-00859-0. Epub 2022 Apr 12.
3. Zhao H#, Ma Y#, Li D, Sun T, Li L, Li P, Liu X, Zhou H, Hou Y, Liu Y, Han P, Zhao Y, Jing F, Peng J*, Hou M*. Low-dose chidamide restores immune tolerance in ITP in mice and humans. Blood. 2019 Feb 14;133(7):730-742. doi: 10.1182/blood-2018-05-847624.
4. Wang R, Yang X, Liu J, Zhong F, Zhang C, Chen Y, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat Commun. 2022 May 9;13(1):2522.
5. Yang X, Liu J, Liu W, Wu H, Wei Y, Guo X, et al. circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation. Leukemia. 2024 Feb 29;
6. Liu N, Xu S, Yao Q, Zhu Q, Kai Y, Hsu JY, Sakon P, Pinello L, Yuan GC, Bauer DE, Orkin SH. Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nat Genet. 2021 Apr;53(4):511-520. doi: 10.1038/s41588-021-00798-y. Epub 2021 Mar 1. Erratum in: Nat Genet. 2021 Mar 17;: PMID: 33649594; PMCID: PMC8038971.
7. Xu S, Luk K, Yao Q, Shen AH, Zeng J, Wu Y, Luo HY, Brendel C, Pinello L, Chui DHK, Wolfe SA, Bauer DE. Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. Blood. 2019 May 23;133(21):2255-2262. doi: 10.1182/blood-2019-01-895094. Epub 2019 Jan 31. PMID: 30704988; PMCID: PMC6533605.
8. Pengcheng Xu; Yajing Zhao; Tianshu Yu; Yafei Yu; Xiaofei Ni; Haoyi Wang; Lu Sun; Panpan Han; Lingjun Wang; Tao Sun; Xinguang Liu; Hai Zhou; Jun Peng; Ming Hou; Yu Hou*; Miao Xu*; Atorvastatin restores imbalance of cluster of differentiation 4 (CD4) + T cells in immune thrombocytopenia in vivo and in vitro, British Journal of Haematology, 2021
9. Jing Qin; Qiang Liu; Anli Liu; Shaoqiu Leng; Shuwen Wang; Chaoyang Li; Ji Ma; Jun Peng; Miao Xu*; Empagliflozin modulates CD4+ T cell differentiation via metabolic reprogramming in immune thrombocytopenia, British Journal of Haematology, 2022, 198(4)：765-775.
10. Yun Wang; Lei Sheng; Fengjiao Han; Qiuyu Guo; Zihan Zhang; Yu Hou; Qi Feng; Hai Zhou; Xuebin Ji; Jun Peng; Ming Hou*; Miao Xu*; Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis, eClinicalMedicine, -02-, 56：2023, 101777.
Facilities & Resources:
Our laboratory has established cell morphology room, central laboratory, cell culture room, molecular biology laboratory, flow cytometry room and stem cell room to provide assistance for the diagnosis, assessment and differential diagnosis of hematological diseases in the whole hospital. At present, it can perform fusion gene quantitative analysis, chromosome analysis, FISH detection, immune typing, MAIPA, platelet function detection and many other leading laboratory tests in China. The Department of hematology has a variety of characteristic diagnosis and treatment techniques, such as chimeric antigen receptor T cell immunotherapy, autologous and allogeneic hematopoietic stem cell transplantation, stem cell apheresis, anti-platelet membrane glycoprotein autoantibody detection, fluorescence in situ hybridization, platelet aggregation function detection, leukemia fusion gene detection.
Collaborations & Partnerships:
We believe in the power of collaboration. That's why we have forged partnerships with Karolinska Institutet, Lund University, Comptons University of Madrid, University of Toronto, Tianjin Blood Research Institute, Peking University People's Hospital to further advance our research.
Our research group has already established long-term cooperative relationships with University of Toronto in Canada, and Lund University in Sweden. Both University of Toronto and the John Semple group at Lund University are at the international forefront of research in the field of ITP, with extensive experience in constructing ITP mouse models and conducting related animal experiments.
Recreational Activities:
Aside from their profound contributions to medical research, they have rich personal interests. Such as Prof. Ma Daoxin, he avidly reads a diverse range of books, spanning from the latest scientific studies to works in literature and history, finding both inspiration and relaxation in this pursuit. Additionally, running is a cherished hobby for him. It serves not just as physical exercise but also as a means for stress relief and contemplation. Miao Xu’s passions extend beyond the laboratory to the vibrant world of performing arts and music.
Other Features:
Special research areas in the hematology Department include primary immune thrombocytopenia and acute leukemia. Among them, the ITP pathogenesis, specific diagnosis and targeted intervention strategies are at the international and domestic advanced level, and the biological behavior abnormalities, drug resistance and intervention reversal of leukemia are at the domestic advanced level.
Contact:
For more information or inquiries, please visit our website at https://www.qiluhospital.com/list-328-1.html .
Jun Peng：junpeng88@sina.com
Shuqian Xu：shuqian.xu@email.sdu.edu.cn
Daoxin Ma；daoxinma@sdu.edu.cn
Miao Xu：miao.xu@sdu.edu.cn
